A New Form of Specific Targeting Cancer Immunotherapy Using Anti‐tumor Monoclonal Antibody‐conjugated Lymphokine‐activated Killer Cells

Cross‐linking of effector T cells to target cancer cells augments their tumor lytic activities. Here we describe a new method of conjugating lymphokine‐activated killer (LAK) cells with cancer‐specific monoclonal antibody. The LAK cells were biotinylated, treated with avidin, and conjugated with bio...

Descripción completa

Detalles Bibliográficos
Autores principales: Shiraiwa, Hiroshi, Sekine, Teruaki, Tobisu, Ken‐ichi, Kakizoe, Tadao, Koiso, Kenkichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 1991
Materias:
Rapid Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5918496/
https://www.ncbi.nlm.nih.gov/pubmed/1906847
http://dx.doi.org/10.1111/j.1349-7006.1991.tb01895.x
_version_ 1783317428729544704
author Shiraiwa, Hiroshi
Sekine, Teruaki
Tobisu, Ken‐ichi
Kakizoe, Tadao
Koiso, Kenkichi
author_facet Shiraiwa, Hiroshi
Sekine, Teruaki
Tobisu, Ken‐ichi
Kakizoe, Tadao
Koiso, Kenkichi
author_sort Shiraiwa, Hiroshi
collection PubMed
description Cross‐linking of effector T cells to target cancer cells augments their tumor lytic activities. Here we describe a new method of conjugating lymphokine‐activated killer (LAK) cells with cancer‐specific monoclonal antibody. The LAK cells were biotinylated, treated with avidin, and conjugated with biotinylated monoclonal antibody. These monoclonal antibody‐conjugated LAK cells showed specifically enhanced killing activities against anti‐tumor antibody‐reactive cancer cells, and cold target cells specifically inhibited their activities.
format Online
Article
Text
id pubmed-5918496
institution National Center for Biotechnology Information
language English
publishDate 1991
publisher Blackwell Publishing Ltd
record_format MEDLINE/PubMed
spelling pubmed-59184962018-05-11 A New Form of Specific Targeting Cancer Immunotherapy Using Anti‐tumor Monoclonal Antibody‐conjugated Lymphokine‐activated Killer Cells Shiraiwa, Hiroshi Sekine, Teruaki Tobisu, Ken‐ichi Kakizoe, Tadao Koiso, Kenkichi Jpn J Cancer Res Rapid Communication Cross‐linking of effector T cells to target cancer cells augments their tumor lytic activities. Here we describe a new method of conjugating lymphokine‐activated killer (LAK) cells with cancer‐specific monoclonal antibody. The LAK cells were biotinylated, treated with avidin, and conjugated with biotinylated monoclonal antibody. These monoclonal antibody‐conjugated LAK cells showed specifically enhanced killing activities against anti‐tumor antibody‐reactive cancer cells, and cold target cells specifically inhibited their activities. Blackwell Publishing Ltd 1991-06 /pmc/articles/PMC5918496/ /pubmed/1906847 http://dx.doi.org/10.1111/j.1349-7006.1991.tb01895.x Text en
spellingShingle Rapid Communication
Shiraiwa, Hiroshi
Sekine, Teruaki
Tobisu, Ken‐ichi
Kakizoe, Tadao
Koiso, Kenkichi
A New Form of Specific Targeting Cancer Immunotherapy Using Anti‐tumor Monoclonal Antibody‐conjugated Lymphokine‐activated Killer Cells
title A New Form of Specific Targeting Cancer Immunotherapy Using Anti‐tumor Monoclonal Antibody‐conjugated Lymphokine‐activated Killer Cells
title_full A New Form of Specific Targeting Cancer Immunotherapy Using Anti‐tumor Monoclonal Antibody‐conjugated Lymphokine‐activated Killer Cells
title_fullStr A New Form of Specific Targeting Cancer Immunotherapy Using Anti‐tumor Monoclonal Antibody‐conjugated Lymphokine‐activated Killer Cells
title_full_unstemmed A New Form of Specific Targeting Cancer Immunotherapy Using Anti‐tumor Monoclonal Antibody‐conjugated Lymphokine‐activated Killer Cells
title_short A New Form of Specific Targeting Cancer Immunotherapy Using Anti‐tumor Monoclonal Antibody‐conjugated Lymphokine‐activated Killer Cells
title_sort new form of specific targeting cancer immunotherapy using anti‐tumor monoclonal antibody‐conjugated lymphokine‐activated killer cells
topic Rapid Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5918496/
https://www.ncbi.nlm.nih.gov/pubmed/1906847
http://dx.doi.org/10.1111/j.1349-7006.1991.tb01895.x
work_keys_str_mv AT shiraiwahiroshi anewformofspecifictargetingcancerimmunotherapyusingantitumormonoclonalantibodyconjugatedlymphokineactivatedkillercells
AT sekineteruaki anewformofspecifictargetingcancerimmunotherapyusingantitumormonoclonalantibodyconjugatedlymphokineactivatedkillercells
AT tobisukenichi anewformofspecifictargetingcancerimmunotherapyusingantitumormonoclonalantibodyconjugatedlymphokineactivatedkillercells
AT kakizoetadao anewformofspecifictargetingcancerimmunotherapyusingantitumormonoclonalantibodyconjugatedlymphokineactivatedkillercells
AT koisokenkichi anewformofspecifictargetingcancerimmunotherapyusingantitumormonoclonalantibodyconjugatedlymphokineactivatedkillercells
AT shiraiwahiroshi newformofspecifictargetingcancerimmunotherapyusingantitumormonoclonalantibodyconjugatedlymphokineactivatedkillercells
AT sekineteruaki newformofspecifictargetingcancerimmunotherapyusingantitumormonoclonalantibodyconjugatedlymphokineactivatedkillercells
AT tobisukenichi newformofspecifictargetingcancerimmunotherapyusingantitumormonoclonalantibodyconjugatedlymphokineactivatedkillercells
AT kakizoetadao newformofspecifictargetingcancerimmunotherapyusingantitumormonoclonalantibodyconjugatedlymphokineactivatedkillercells
AT koisokenkichi newformofspecifictargetingcancerimmunotherapyusingantitumormonoclonalantibodyconjugatedlymphokineactivatedkillercells

Ejemplares similares